No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TWST240719P47500
- 1.95
- -0.55-22.00%
15min DelayClose Jul 1 15:59 ET
1.95High1.95Low
1.95Open2.50Pre Close1 Volume117 Open Interest47.50Strike Price195.00Turnover71.94%IV6.91%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry1.95Extrinsic Value100Contract SizeAmericanOptions Type-0.3897Delta0.0493Gamma20.82Leverage Ratio-0.0818Theta-0.0095Rho-8.11Eff Leverage0.0416Vega
Intraday
- 5D
- Daily
News
Is Twist Bioscience Corporation (TWST) a Good Stock to Buy and Hold for 5 Years?
Form 144 | Twist Bioscience(TWST.US) Officer Proposes to Sell 906.74K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Twist Bioscience(TWST.US)$ Officer Banyai William intends to sell 18,777 shares of its common stock on Jul 1, with a total market value of approximately $906.74K. Ban
Twist Bioscience Is Maintained at Overweight by Barclays
Express News | Twist Bioscience : Barclays Raises Target Price to $60 From $45
Barclays Maintains Twist Bioscience(TWST.US) With Buy Rating, Raises Target Price to $60
Here's Why We're Not At All Concerned With Twist Bioscience's (NASDAQ:TWST) Cash Burn Situation
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
Twist Bioscience's P/S ratio remains lower due to sub-par revenue outlook, indicating investor expectation of limited future growth. Shareholder pessimism around future revenue growth contributes to this lower ratio.
Twist Bioscience's optimistic cash runway and manageable burn rate are noteworthy despite the need for vigilance as the firm grows. Its market cap also points to easy fundraising potential.
Despite Twist Bioscience's unprofitability, rapid revenue growth indicates positive prospects. However, persistent share price decline hints at capital raising issues. Investors should assess the firm's balance sheet, market conditions and specific risks.
$Twist Bioscience(TWST.US$ Twist Bioscience Announced An Antibody Discovery, Option And License Agreement With Bayer Of Up To $188M. Bayer Will Have The Option To License Antibodies Discovered Under The Collaboration
Read more